Susquehanna International Group Ltd. Takes $588,000 Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Susquehanna International Group Ltd. purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,000 shares of the biotechnology company’s stock, valued at approximately $588,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AXON. 9258 Wealth Management LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at about $204,000. Cambridge Investment Research Advisors Inc. boosted its holdings in Axon Enterprise by 6.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 8,251 shares of the biotechnology company’s stock worth $2,131,000 after acquiring an additional 535 shares in the last quarter. Advisory Services Network LLC bought a new position in Axon Enterprise in the fourth quarter worth approximately $180,000. Hsbc Holdings PLC boosted its holdings in Axon Enterprise by 53.0% in the fourth quarter. Hsbc Holdings PLC now owns 113,944 shares of the biotechnology company’s stock worth $29,408,000 after acquiring an additional 39,479 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in Axon Enterprise by 5.5% in the fourth quarter. TD Asset Management Inc now owns 23,575 shares of the biotechnology company’s stock worth $6,090,000 after acquiring an additional 1,233 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON opened at $395.34 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $29.88 billion, a price-to-earnings ratio of 115.60, a PEG ratio of 10.55 and a beta of 0.94. The stock has a 50 day moving average of $356.27 and a 200 day moving average of $320.00. Axon Enterprise, Inc. has a 12 month low of $190.01 and a 12 month high of $398.74.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. During the same period last year, the business posted $0.80 earnings per share. As a group, sell-side analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Insider Activity at Axon Enterprise

In related news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the sale, the chief financial officer now directly owns 98,825 shares of the company’s stock, valued at $37,449,733.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the completion of the sale, the chief financial officer now directly owns 98,825 shares of the company’s stock, valued at $37,449,733.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the sale, the director now directly owns 27,259 shares of the company’s stock, valued at $10,385,406.41. The disclosure for this sale can be found here. Over the last three months, insiders sold 317,981 shares of company stock valued at $115,662,734. 6.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AXON. Barclays increased their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Craig Hallum increased their price target on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America began coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target on the stock. Finally, Northland Securities increased their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $365.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.